Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects

NCT07697560 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Chemotherapy-induced Peripheral Neuropathy (CIPN)

Interventions

DRUG: AH-008 for Injection, 150 mg
DRUG: AH-008 for Injection, Placebo

Sponsor

AnHorn Medicines Co. Ltd.